PMID: 11907179Mar 22, 2002Paper

Differential effects of sarcolemmal and mitochondrial K(ATP) channels activated by 17 beta-estradiol on reperfusion arrhythmias and infarct sizes in canine hearts

The Journal of Pharmacology and Experimental Therapeutics
Chang-Her TsaiTsung-Ming Lee

Abstract

We have demonstrated the effects of estrogen on modulation of ATP-sensitive K(+) channels; however, the subcellular location of these channels is unknown. The purpose of the present study was to investigate the role of the sarcolemmal and mitochondrial ATP-sensitive K(+) channels in a canine model of myocardial infarction after stimulation with 17 beta-estradiol. Anesthetized dogs were subjected to 60 min of the left anterior descending coronary artery occlusion followed by 3 h of reperfusion. Infarct size was markedly reduced in estradiol-treated dogs compared with controls (14 +/- 6 versus 42 +/- 6%, P < 0.0001), indicating the effective dose of estradiol administrated. Pretreatment with the mitochondrial ATP-sensitive K(+) channel antagonist 5-hydroxydecanoate completely abolished estradiol-induced cardioprotection. The sarcolemmal ATP-sensitive K(+) channel antagonist 1-15-12-(5-chloro-o-anisamido)ethyl-methoxyphenyl)sulfonyl-3-methylthiourea (HMR 1098) did not significantly attenuate estradiol-induced infarct size limitation. In addition, estradiol administration significantly reduced the incidence and duration of reperfusion-induced ventricular tachycardia and ventricular fibrillation. Although 5-hydroxydecanoate alone ca...Continue Reading

References

Mar 1, 1990·Journal of Cardiovascular Pharmacology·L ChiB R Lucchesi
Jan 1, 1989·Pflügers Archiv : European journal of physiology·D Escande
Sep 1, 1995·Journal of the American College of Cardiology·K SudhirK Chatterjee
Jan 1, 1997·Advances in Experimental Medicine and Biology·J M Downey, M V Cohen
Feb 7, 1998·Naunyn-Schmiedeberg's Archives of Pharmacology·F BergerT M Weis
Feb 17, 1999·Journal of Molecular and Cellular Cardiology·S PicardJ L Gérard
May 4, 1999·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N JovanovićA Terzic
Jun 29, 1999·British Journal of Pharmacology·T NakajimaH Hazama
Aug 24, 1999·The Journal of Physiology·E L HolmuhamedovA Terzic
Sep 11, 1999·The American Journal of Cardiology·B W RobinsonE Eshaghpour
May 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·K S RussellJ R Bender
Jul 14, 2001·Molecular and Cellular Biochemistry·E L HolmuhamedovA Terzic

❮ Previous
Next ❯

Citations

Aug 7, 2008·Cardiovascular Toxicology·Erin A Booth, Benedict R Lucchesi
Apr 28, 2005·Free Radical Biology & Medicine·Scott W Ballinger
Jul 14, 2010·Cardiovascular Research·David A Brown, Brian O'Rourke
Sep 23, 2008·Journal of Cardiovascular Pharmacology·Erin Anne BoothBenedict R Lucchesi
Oct 29, 2013·Oxidative Medicine and Cellular Longevity·Anikó PósaCsaba Varga
Jun 27, 2006·The Annals of Thoracic Surgery·James D McCullySidney Levitsky
Aug 19, 2007·European Journal of Pharmacology·Karen L PhilpSusan J Coker
Nov 14, 2018·European Heart Journal. Acute Cardiovascular Care·Kirian van der WegAnton Pm Gorgels
Jul 5, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Erin A BoothBenedict R Lucchesi
Jun 27, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Tsung-Ming LeeNen-Chung Chang
Apr 17, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Erin A Booth, Benedict R Lucchesi
May 27, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Matthias J MerkelDonna M Van Winkle
Apr 7, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Chih-Sen KangTsung-Ming Lee
Aug 2, 2003·The Journal of Pharmacology and Experimental Therapeutics·Erin A BoothBenedict R Lucchesi
Feb 8, 2003·The Journal of Clinical Endocrinology and Metabolism·Tsung-Ming Lee, Tsai-Fwu Chou
Jul 17, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Heidi L LujanStephen E DiCarlo
Oct 4, 2012·Neuroreport·Dengwen ZhangXueren Wang
Jan 13, 2021·International Journal of Molecular Sciences·Jaqueline S da SilvaGisele Zapata-Sudo
Jul 11, 2006·Experimental Cell Research·Vassilia-Ismini AlexakiElias Castanas
Aug 1, 2006·Journal of Molecular and Cellular Cardiology·Ana B RoperoEnrico Stefani
Dec 5, 2006·Journal of Molecular and Cellular Cardiology·R TissierB Ghaleh
Apr 26, 2011·Pharmacology & Therapeutics·Fadi G Akar, Brian O'Rourke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.